Park Mi Hee, Kim Jong Han, Chung Young-Ho, Lee Seung Ho
The Hormel Institute, University of Minnesota, United States; Division of Life Science, Korea Basic Science Institute, Daejeon, Republic of Korea.
Botanical Drug Laboratory, Korea Ginseng Corporation, Yuseong-gu, Daejeon, Republic of Korea.
Biochem Biophys Res Commun. 2016 Apr 29;473(2):586-92. doi: 10.1016/j.bbrc.2016.03.127. Epub 2016 Mar 28.
We investigated whether bakuchiol, an analog of resveratrol enhances the apoptosis ability of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in cancer cells. Bakuchiol enhanced expression of cell death receptor (DR) in TRAIL-sensitive and -resistant colon cancer cells in a dose-dependent manner. A combination of bakuchiol with TRAIL significantly inhibited cell growth of TRAIL sensitive HCT116 and TRAIL resistant HT-29 cells. The expression of TRAIL receptors; DR4 and DR5 was significantly increased by treatment of bakuchiol, however, the expression of survival proteins (e.g., cFLIP, survivin, XIAP and Bcl2) was suppressed. Moreover, the expression of apoptosis related proteins such as cleaved caspase-3, -8, -9 and PARP was increased by combination treatment of bakuchiol and TRAIL. Depletion of DR4 or DR5 by small interfering RNA significantly reversed the cell growth inhibitory effects of bakuchiol in HCT116 and HT-29 cells. Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the bakuchiol induced cell growth inhibitory effects. The collective results suggest that bakuchiol facilitates TRAIL-induced apoptosis in colon cancer cells through up-regulation of the TRAIL receptors; DR4 and DR5 via ROS/JNK pathway signals.
我们研究了白藜芦醇类似物补骨脂酚是否能增强肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)在癌细胞中的凋亡能力。补骨脂酚以剂量依赖的方式增强了TRAIL敏感和耐药结肠癌细胞中细胞死亡受体(DR)的表达。补骨脂酚与TRAIL联合使用可显著抑制TRAIL敏感的HCT116细胞和TRAIL耐药的HT-29细胞的生长。补骨脂酚处理后,TRAIL受体DR4和DR5的表达显著增加,然而,存活蛋白(如cFLIP、survivin、XIAP和Bcl2)的表达受到抑制。此外,补骨脂酚和TRAIL联合处理可增加凋亡相关蛋白如裂解的caspase-3、-8、-9和PARP的表达。用小干扰RNA耗尽DR4或DR5可显著逆转补骨脂酚对HCT116和HT-29细胞的生长抑制作用。用c-Jun氨基末端激酶(JNK)抑制剂SP600125和活性氧(ROS)清除剂N-乙酰半胱氨酸预处理可降低补骨脂酚诱导的细胞生长抑制作用。总体结果表明,补骨脂酚通过上调TRAIL受体DR4和DR5,经由ROS/JNK信号通路促进TRAIL诱导的结肠癌细胞凋亡。